CuraGen Announces Top-Line Phase II Results on Velafermin
- Conference call to be hosted today at 8:30 a.m. Eastern Time - BRANFORD, Conn., Oct. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II dose-confirmatory clinical trial (CLN-...CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
... Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis - -...ate on the Company's clinical programs including: velafermin for the prevention of severe oral mucositis (OM): ...ng the efficacy and safety of a single infusion of velafermin for the prevention of severe OM. A total of 390 pa...